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1. Intoduction 
Heparin is an effective anti-coagulant for the prevention of venous thromboembolism and 
for the treatment of venous thrombosis and pulmonary embolism (Girolami et al., 2003; 
Hirsh et al., 2004; Shantsila et al., 2009). It is often used for patients with unstable angina and 
acute myocardial infarction, and for patients who have undergone vascular surgery 
(Battistelli et al., 2010). The administration of heparin frequently induces a reduction in 
platelet counts. This phenomenon is called heparin-induced thrombocytopenia (HIT) and be 
classified as either type I or II. To avoid confusion between the syndromes, “HIT type I” has 
been changed to “non-immune heparin associated thrombocytopenia”, and ‘‘HIT type II’’ is 
simply called ‘‘HIT’’. 
The origin of non-immune heparin associated thrombocytopenia is not yet completely 
understood, though it is thought to be caused by heparin-induced platelet clumping (Fabris 
et al., 1983; Chong & Ismail, 1989). Thrombocytopenia of this type is mild (platelet count, 
>100 x 109 cells/L), not progressive, nor associated with bleeding or thrombosis (Salzman et 
al., 1980), and is independent of any immune reaction (Chong et al., 1993a; Burgess & 
Chong, 1997; Shantsila et al., 2009). It is characterized by a transitory, slight and 
asymptomatic reduction in platelet count, occurring during the first 1-2 days of heparin 
administration. This phenomenon gradually resolves without interruption of heparin 
administration, and platelet counts gradually rises to pre-treatment levels within a few days 
without special treatment. Non-immune heparin associated thrombocytopenia may be 
related to the direct binding of heparin to platelet membranes (Salzman et al., 1980; Fabris et 
al., 1983; Chong & Ismail, 1989).  
In this view, the term HIT refers only to HIT type II. HIT is associated with a heparin-related 
immune reaction. It is a prothrombotic disease initiated by administration of heparin, and is 
related to antibody-mediated platelet activation causing thrombin generation and 
thrombotic complications. Thrombocytopenia is common in hospitalized patients, occurring 
in up to 58% of critically ill individuals, and can be caused by a variety of factors (Strauss et 
al., 2002). HIT, which is associated with significant morbidity and mortality if unrecognized, 
can be regarded as a very severe side effect of a drug, (Chong, 1992; Aster, 1995; Chong, 
2003). Unfortunately, HIT often remains unrecognized, undiagnosed, and untreated, a 
problem that can be rectified with increased awareness and a high degree of suspicion for 
HIT. Current treatment recommendations are based on recent advances in research on the 
pathophysiology and the natural history of HIT (Jang & Hursting, 2005). HIT should be 
considered a clinicopathologic syndrome (Warkentin et al., 1998; Warkentin, 2002, 2003) 
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since its diagnosis is based on both clinical criteria, such as thrombocytopenia and 
thrombosis, and laboratory data, such as platelet count dynamics and the detection of HIT 
antibodies (Shantsila et al., 2009).  
However, HIT is often difficult to diagnose because of the following phenomena: 1) 
nonimmune heparin-associated thrombocytopenia occurs in 10-30% of patients receiving 
heparin (Blank et al., 2002); 2) HIT antibody seroconversion is observed in the absence of 
thrombocytopenia or other clinical sequelae; and 3) enzyme-linked immunosorbent assay 
(ELISA) detects both clinically irrelevant (non-pathogenic) and clinically relevant 
(pathogenic) antibodies (Shantsila et al., 2009). Seroconversion of anti-HIT antibody without 
thrombocytopenia or other clinical sequela is not considered HIT, whereas a diagnosis of 
HIT can be made when anti-HIT antibody formation is accompanied by an otherwise 
unexplained platelet count fall, or by skin lesions at heparin injection sites or acute systemic 
reactions after intravenous injection of heparin (Bartholomew et al., 2005). Furthermore, HIT 
formation may also be related to the occurrence of venous limb gangrene occurring in HIT 
patients treated with oral anticoagulants (Warkentin, 1996a). A mnemonic device, the “4 Ts” 
of HIT, has been developed to remember the salient clinical features of HIT, thus facilitating 
patient assessment and HIT diagnosis (Warkentin & Heddle, 2003): the degree of 
Thrombocytopenia, the Timing of the platelet fall, the presence of Thrombosis or other 
sequelae, and oTher potential causes of thrombocytopenia (Lillo-Le Louët et al., 2004; Denys 
et al., 2008; Gruel et al., 2008).  
Despite the utility of this memory device, severe morbidity and mortality in HIT patients 
persists because of lack of awareness accompanied by a delayed diagnosis. Thus, we have 
developed the following chapter to provide an overview of HIT, focusing particularly on the 
epidemiology, pathophysiology, diagnosis, laboratory evaluation, and treatment. 
2. Overview of HIT 
HIT type II, namely, HIT, is immune-mediated and associated with a risk of thrombosis. It 
develops in approximately 5-10% of patients treated with heparin and is characterized by a 
significant reduction in platelets (levels fall by 30% or more), generally after the fifth day of 
therapy (Warkentin et al., 1998; Warkentin, 2002). Although, this phenomenon is usually 
resolved by therapy within 5-15 days, some cases may require months of treatment (Chong, 
1992; Warkentin et al., 1998; Warkentin, 2002).  
Platelet count monitoring is recommended for heparin-treated patients in whom the risk of 
HIT is high (e.g., postoperative patients) or intermediate (e.g., medical or obstetric patients 
receiving a prophylactic dose of heparin or postoperative patients receiving antithrombotic 
prophylaxis) (Chong et al., 1993a; Jang & Hursting, 2005). Shantsila et al. (2009) have 
recommended measurement of platelet counts before, and 24 h after, initiation of heparin 
therapy in patients who have received heparin within the past 100 days. Platelet counts 
should also be performed every 2-3 days in intermediate-risk patients, every other day in 
high-risk patients, and immediately in patients with systemic, cardiorespiratory, or 
neurologic symptoms that occur within 30 min after an intravenous injection of heparin.  
HIT should be suspected when thrombocytopenia (<15-20 109 cells/L, or a >50% decrease 
in platelet count) occurs during heparin administration, typically 5-14 days after initiation 
of heparin administration (Warkentin & Kelton, 2001a); however, very severe 
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thrombocytopenia (platelet count <15-20 109 cells/L) is generally not due to HIT. Routine 
platelet count monitoring for HIT may be appropriate in a least some clinical situations, and 
it may be reasonable to stratify the intensity of need for platelet count monitoring in relation 
to the risk of HIT.  
Although it is difficult to predict which heparin-exposed patients will develop HIT, one 
consistent factor is a property of heparin preparation. HIT antibodies occur at higher levels 
in patients given bovine unfractionated heparin (UFH) than in those treated with porcine 
UFH or low molecular weigh heparin (LMWH) (Green et al., 1984; Bailey et al., 1986; 
Monreal et al., 1989; Rao et al., 1989; Warkentin et al., 1995; Warkentin et al., 2003a; Lee & 
Warkentin, 2004; Denys et al., 2008; Gruel et al., 2008).  
HIT antibody formation is also influenced by the medical circumstances in which heparin is 
administered. For example, approximately 20% of heparin-exposed patients develop HIT 
antibodies after orthopedic surgery, while as many as 70% develop antibodies after 
receiving a cardiopulmonary bypass (CPB) (Amiral et al., 1996a). However, it can be 
difficult to compare results across studies because of differences in duration and route of 
anticoagulant administration, as well as patient group composition (Lee et al., 2004).  
3. Epidemiology  
There is a need for studies on HIT incidence. The work that has been done is sufficient, and 
they have so many differences that it is difficult to compare results across studies in order to 
uncover broader trends. Most HIT studies are retrospective, and differ with respect to 
patient characteristics, type of heparin preparation, duration of therapy, definition of 
thrombocytopenia, and laboratory tests used for confirm thrombocytopenia diagnosis 
(Schmitt & Adelman, 1993; Magnani, 1993; Chong, 2003). Despite these problems, it is 
possible to draw some general conclusions about HIT epidemiology.  
There are 3 characteristic profiles in the timing of the onset of thrombocytopenia. 
Approximately 70% of HIT patients are classified as “typical-onset HIT”. In these patients, 
platelet counts begin to decrease (serocnversion and initial platelet count fall) within 5-10 days 
after beginning heparin treatment (Warkentin & Kelton, 2001a). Approximately 25-30% of HIT 
patients are classified as having “Rapid-onset HIT”, which occurs when platelet counts fall 
abruptly within 24 h of starting heparin therapy (Warkentin & Kelton, 2001a; Lubenow et al., 
2002). “Rapid-onset HIT” is strongly associated with recent heparin exposure, usually within 
the preceding 100 days (Warkentin & Kelton, 2001a; Lubenow et al., 2002). Because of the 
previous exposure, patients already have circulating HIT antibodies, which cause platelet 
counts to fall quickly once heparin is re-administered. The last category of HIT, affecting 
approximately 3-5% of HIT patients, is “delayed-onset HIT” in which the onset of 
thrombocytopenia begins several days after completion of heparin treatment (Warkentin & 
Kelton, 2001b; Rice et al., 2002; Warkentin & Bernstein, 2003; Warkentin, 2004a). This type of 
syndrome is often clinically severe, as it is associated with high-titer, platelet-activating HIT 
antibodies that do not require ongoing heparin administration to exert their pathogenic effect 
(Rice et al., 2002). Furthermore, this type may occur in patients exposed to minimal amounts of 
heparin, although it has also been observed in patients exposed to large amounts of heparin 
during coronary artery bypass grafting (Rice et al., 2002; Jackson et al., 2006). Rarely, patients 
who received intravenous heparin develop acute inflammatory or cardiorespiratory 
symptoms and signs within 30 min (Warkentin, 2007).  
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HIT severity is mainly determined by the extent of thrombotic complications (Girolami et al, 
2003). Many HIT patients develop thrombosis after receiving as an antithrombotic 
prophylaxis (Warkentin, 1996a; Wallis et al., 1999). The thrombotic event is frequently a 
worsening of pre-existing thrombosis in heparin-treated HIT patients, and this worsening of 
thrombosis may cause a new thromboembolic complication (Magnani, 1993; Warkentin & 
Kelton, 1990, 1996; Nands et al., 1997); this has been observed in approximately 20% of cases 
(Wakentin, 2004a). Development of a new thrombus or extension of an existing thrombus 
during treatment with prophylactic or therapeutic UFH or LMWH should always raise a 
suspicion of HIT (Shantsila et al., 2009). The first event to be associated with HIT was 
arterial thrombosis, which seems to be more frequent in patients with cardiovascular disease 
(Nands et al., 1997); venous complications may be common in patients undergoing post-
surgical prophylaxis (Rhodes et al., 1973; Magnani, 1993; Warkentin & Kelton, 1996;). In 
most cases, arterial complications manifest as thromboses of the large vessels, leading to 
gangrene and limb amputation, stroke, myocardial infarction, and cardiac thrombosis 
(Warkentin & Kelton, 1990; Boshkov et al., 1993; Fondu, 1995; Chong, 1995).  
Approximately 10-20% of patients who develop HIT while receiving subcutaneous 
injections of heparin experience skin lesions, ranging from painful erythematous plaques to 
skin necrosis, at the injection sites (Warkentin, 2004a; Chong, 1995). Skin lesions have been 
observed in patients without thrombocytopenia but with circulating HIT antibodies 
(Warkentin, 1996b). Occasionally, HIT associated with intravenous heparin injection also 
manifests as an acute systemic reaction developing within 5-30 min after heprin 
administration (Ansell et al., 1986; Popov et al., 1997; Warkentin, 2004a).  
Estimates of HIT prevalence among heparin-treated patients differ depending on heparin 
type. Fabris et al. (2000) found that laboratory-confirmed HIT occurs in approximately 2% of 
patients receiving UFH. Among patients given therapeutic doses of bovine UFH, HIT has 
been observed in approximately 5% of patients. This is a much higher rate than that 
observed in patients given procine UFH (1%). Prophylactic doses of porcine heparin have 
been reported to cause HIT in <1% of patients (Warkentin & Kelton, 1990). However, risk of 
HIT is relatively low in medical and obstetric patients receiving LMWH (Fabris et al., 2000). 
For instance, Warkentin (2004a) reorted that HIT was observed in 2.7% of patients treated 
with subcutaneous UFH injection, but in no patients receiving LMWH; further, thrombotic 
complications were more frequent in the former group (88.9%) than in the latter (17.8%). 
Both the bovine/procine UFH and the LMWH data were collected from medical patients 
receiving LMWH or UFH as “flushes”, e.g., oncology patients with indwelling catheters 
(Mayo et al., 1990; Kadidal et al., 1999). A randomized controlled trial that compared use of 
porcine UFH with LMWH after hip replacement surgery found that HIT was significantly 
less common among patients who received the latter treatment (Lee & Warkentin, 2004; 
Warkentin, 2004a).  
4. Pathophysiology  
Francis and colleagues have reported that HIT antibody formation in cardiac surgery 
patients who received procine UFH was significantly lower than those with bovine UFH 
(Francis et al., 2003). The IgG fraction of HIT patients serum has been found to cause in vitro 
platelet aggregation in the presence of therapeutic amounts of heparin (Rhodes et al., 1973), 
indicating that HIT has an immunologic etiology (Amiral et al., 1998; Warkentin et al., 2000). 
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Green et al. (1978) reported that immunoglobulin-heparin complexes form only in the 
presence of platelets (Green et al., 1978), and several platelet proteins have been proposed as 
the receptors of heparin-dependent antibodies (Lynch & Howe, 1985). Multiple studies have 
found that the pro-aggregating effect of heparin depends on the degree of sulfation and the 
molecular weight of the heparin (Geinacher et al., 1992; Geinacher et al., 1993; Kelton et al., 
1994) and is mediated by the release of platelet alpha-granules (Gruel et al., 1993), which 
contain platelet factor 4 (PF4), a small, positively charged molecule produced by 
megakaryocytes. Although its biological function is unknown, it has been identified as the 
main co-factor of heparin (Amiral et al., 1992, Gentilini et al., 1999); it also binds to 
endothelial-surface glycosaminoglycans, e.g., heparin sulfate (Visentin et al., 1994; Cines et 
al., 2007). Normal blood levels of PF4 are very low, as it is only released into circulation 
following weak platelet activation. However, PF4 levels may be high in specific clinical 
circumstances, such as prosthetic hip or cardiac surgery, which are associated with platelet 
activation (Greinacher et al., 1994a). When heparin binds with PF4, it undergoes a 
conformational change and becomes immunogenic, leading to the generation of anti-
heparin/PF4 antibodies, namely, HIT antibodies (Suh et al., 1998; Ziporen et al., 1998). The 
PF4/heparin ratio is important for the constitution of the multimolecular antigenic complex, 
and the optimal PF4/heparin ratio has been reported to range from 4-6:1 (Kelton et al., 1994; 
Visentin et al., 1994; Amiral et al., 1995; Cines et al., 2007). The immunogenicity of heparin-
PF4 conjugates may form the biological basis for differences in immunogenicity between 
bovine and porcine sources of heparin: Bovine lung heparin has longer polysaccharide 
chains and a higher degree of sulfation, which could increase reactivity with PF4 (Boshkov 
et al., 1993).  
HIT antibodies activate platelets and stimulate an immunomedited endothelial lesion, 
followed by the appearance of thrombocytopenia and/or thrombosis (Fondu, 1995; 
Greinacher, 1995; Warkentin et al., 1998; Cines et al., 2007). Platelet activation is primarily 
caused by binding between the immunocomplex and FcγRIIa (CD32) receptors (Adelman et 
al., 1989; Anderson et al., 1995; Baglin, 2001), leading to degranulation and the release of 
pro-coagulant substances (e.g., serotonin, histamine, and adenosine diphosphate), 
thromboxane biosynthesis, an influx of Ca2+, and the generation of highly pro-thrombotic 
phospholipid microparticles (Chong et al., 1981; Chong et al., 1989a; Warkentin & Kelton, 
2001a). The immunocomplex can bind to Fc receptors on the surfaces of monocytes, 
neutrophils, and endothelial cells, and the binding of the immunocomplex to so many types 
of cells can contribute to the profound thrombin generation seen in patients with HIT. 
Thrombin generation can be enhanced by HIT activation of monocytes and endothelial cell 
tissue factor on the surface of monocytes and endothelial cells (Visentin et al., 1994; 
Warkentin, 1999; Newman & Chong, 2000; Pouplard et al., 2001; Arepally & Mayer, 2001). 
These thrombotic processes may lead to a hypercoagulable state, thus increasing the risk of 
severe and extensive thromboembolic complications in many patients. Additional activation 
of platelets by thrombin and other released agonists results in a further increase in the 
numbers of FcγRIIa receptors on the platelet surface, facilitating even more platelet 
activation (Chong et al., 1993b; Anderson et al., 1995). However, some reports have 
indicated that platelet activation can be blocked by the FcγRIIa receptor-specific monoclonal 
antibody (IV.3) (Kelton et al., 1988; Visentin et al, 1994).  
While IgG-class HIT antibody can be detected in most HIT patients, IgA and IgM HIT 
antibodies can be found in only a small portion of patients (Suh et al., 1997; Amiral et al., 
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1996b). Given that IgA and IgM antibodies do not activate platelets in the presence of 
heparin in vitro, and that they are unable to bind FcγRIIa, their presence in HIT patients 
could simply be coincidental, though IgM and IgA are not able to bind to FcγRIIa (Amiral et 
al., 1996a; Amiral et al., 1996b; Amiral et al., 1996c; Blank et al., 1997). These data suggest 
that platelet activation occurs independently of the IgG FcγRIIa receptor. After heparin 
administration is interrupted, the HIT antibody gradually disappears; laboratory tests for 
HIT antibodies are usually “negative” or “weakly positive” at 100 days (Shantsila et al., 
2009). For HIT to develop at this point, the HIT antibody would need to form again 
(Lubenow et al., 2002; Rice et al., 2002). Harris et al. (2008) have reported an association 
between the PLA2 polymorphism of glycoprotein IIIa and the risk of thrombosis in patients 
with HIT antibodies.  
5. Diagnosis of HIT  
The diagnosis of HIT should be based both on clinical criteria, such as the presence of 
thrombocytopenia and thrombosis, and laboratory data, such as platelet count dynamics 
and detection of HIT antibodies. However, it may be difficult to establish a general 
diagnostic protocol, given the lack of a readily accessible standard laboratory test and the 
frequent detection of elevated anti-HIT antibody levels in heparin-treated patients that 
display no clinical features of the disease (Arepally & Ortel, 2006).  
In the majority of patients with HIT, thrombocytopenia is defined as an otherwise 
unexplained >50% drop in the platelet count (Warkentin et al., 2008a); thrombocytopenia is 
generally of moderate severity, and median platelet count is approximately 50-60 x 109 
platelets/L (Jackson et al., 2006). In HIT patients, platelet counts are generally < 20 x 109 
platelets/L. Clinical presentation of HIT in patients with profound thrombocytopenia can be 
rapidly progressive and include the development of disseminated intravascular coagulation 
and microvascular thrombotic complications (Ortel, 2009). Patients are likely to suffer from 
HIT when their platelet counts drop to less than 50% of normal levels and when they 
present with thrombosis or skin lesions at heparin injection sites (Jackson et al., 2006). 
Generally, platelet count decreases and/or thrombotic events begin 5–10 days after the 
initiation of heparin therapy in heparin-hypersensitive individuals, and platelet count in 
thrombocytopenic patients may not return to initiation levels until several days later 
(Warkentin & Kelton, 2001a). In patients who have undergone operation, the expected 
pattern would show a return of normal platelet count immediately after surgery, followed 
by an unexpected drop (Warkentin, 2003). Persistent thrombocytopenia following cardiac 
bypass surgery is usually not a result of HIT, but instead may stem from other causes, such 
as postoperative complications. However, postoperative thrombocytopenia lasting for >5 
days without an apparent alternative cause may be the result of HIT (Lillo-Le et al., 2004).  
Several diagnostic algorithms have been developed to provide a more systematic approach 
to the diagnosis of HIT. Patients can be assigned an HIT score using the “4 Ts,” an 
assessment protocol and memory device focused on the salient clinical features of HIT: 
degree of Thrombocytopenia (maximum points for a platelet count fall of >50% or a nadir of 
20–100 × 109/L), the Timing of the fall in platelet count (maximum points for an onset of 5–
10 days after initiation of heparin treatment or within 1 day if there has been recent heparin 
exposure), the presence of Thrombosis or other sequelae (maximum points for new 
thrombosis, skin lesions, or acute systemic reactions), and oTher causes of 
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thrombocytopenia excluded (maximum points for no other cause event) (Warkentin, 2003, 
Warkentin et al., 2003b, Bryant et al., 2008). The “4 Ts” is useful for following the 
recommendation of Warkentin and Heddle, who suggest the employment of a clinical 
decision–making model to establish a pretest probability for HIT in patients who receive 
UFH or LMWH (Warkentin & Heddle, 2003). A diagnostic score for HIT after 
cardiopulmonary bypass surgery has also been proposed (Lillo-Le et al., 2004). Other 
studies have demonstrated the usefulness of combining the 4Ts score with laboratory testing 
when diagnosing HIT (Lillo-Le et al., 2004; Denys et al., 2008; Gruel et al., 2008); laboratory 
tests can also be used independently for confirming a clinical diagnosis.  
5.1 Laboratory testing  
Laboratory testing is necessary to confirm the diagnosis of HIT, and is most helpful in these 
patients clinically assessed to be at intermediate high clinical risk of HIT (Arepally & Ortel, 
2006). Patients who have undergone cardiopulmonary bypass surgery frequently have 
elevated antiheparin/PF4 antibody levels; among these individuals, testing should not be 
used to “screen” patients for HIT or evaluate patients assessed to have a low pre-test 
probability for HIT (Warkentin et al., 2008a). Although a lot of laboratory tests are available 
for detection of heparin-PF4 antibody, these tests have several advantages and 
disadvantages. Blood sampling for the detection of HIT antibodies was performed in 
patients with clinically suspected HIT on days 5 to 14 following the initiation of heparin 
therapy (Warkentin et al., 2008a). Although HIT antibodies are detectable in the blood for 
several weeks after heparin administration, discontinuation of heparin administration, 
samples should be collected as soon as possible because antibody levels can decrease quite 
rapidly. 
The first test developed for diagnosing HIT was the platelet aggregation test, which uses 
citrated platelet-rich plasma (PRP) and standard platelet aggregometry (Warkentin, 2004b). 
The platelet aggregation test is able to provide results quickly (Kelton et al, 1988), although 
results of this test is more influenced by heparin concentrations and donor platelet 
variability compared to those of 14C-serotonin release assay (SRA) (Warkenin & Kelton, 
1990; Chong, 1992, 1995). Accordingly, to increase sensitivity and specificity, test conditions 
need to be optimized– instance, by washed platelets (Chong et al., 1993a; Greinacher et al., 
1994a; Pouplard et al., 1999a). Washed platelet activation assays, such as the platelet SRA, 
(Sheridan et al., 1986; Warkentin et al., 1992; Warkentin, 2001; Price E et al., 2007), and the 
heparin-induced platelet activation test (Greinacher et al., 1991; Greinacher et al,. 1994a) are 
used by a few reference laboratories. In these assays, it is necessary to use of apyrase in a 
wash step for maintenance of platelet reactivity to HIT antibodies, and to resuspend in a 
calcium- and magnesium-containing buffer (Polgár et al., 1998; Warkentin, 2001). The major 
limitation of this method is its technically demanding nature (Warkentin, 2000), which limits 
its use to a few reference laboratories. In most clinical laboratories, immunological tests such 
as ELISA are used because they are easy to perform, have a rapid turnaround time, and are 
highly sensitive (Price et al., 2007). There are 2 PF4-dependent antigen assays that are 
commercially available for detecting HIT antibodies (Amiral et al., 1992; Collins et al., 1997; 
Warkentin, 2000; Warkentin et al., 2001): the Asserachrom (Stago, Asnières, France), which 
detects antibodies that react with PF4-heparin complexes, and the GTI-PF4 (GTI, Brookfield, 
WI, USA), which detects antibodies that react with PF4 bound to polyvinyl sulfonate. 
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Prospective studies have shown that, among HIT antibody classes, only HIT-IgG antibodies 
have very high sensitivity for diagnosing clinical HIT (Warkentin et al., 2000; Lindhoff-Last 
et al., 2001). Detection of PF4-heparin antibodies is performed as followed. Unbound 
material is removed, and a chromogen is added to label the bound conjugate, producing a 
yellow color, read at 405 nm. The amount of yellow produced at the end point, as indicated 
by the optical density (OD), is proportional to the amount of antibody present. A positive 
result is reported if OD reading is 0.400 or more. Higher ELISA OD results have been shown 
to significant correlation of the serotonin release assay results and an increased risk for 
thrombosis in patients with HIT (Warkentin et al., 2008b). Furthermore, the ELISA results 
are most useful when combined with a clinical scoring system (Janatpour et al., 2007). 
Zwicker et al (2004) have reported that higher ELISA OD measurements correlated 
significantly with thrombosis, and patients with isolated HIT (HIT in the absence of 
thrombosis) and an OD level of 1.0 or more had a 6-fold increased risk of thrombosis 
compared with patients who had OD levels between 0.4 and 0.99 (Zwicker et al, 2004). The 
sensitivity of the ELISA for PF4-heparin antibodies is greater than functional assays 
(Greinacher et al., 1994b; Amiral et al., 1995; Pouplard et al., 1999b), though a “positive” 
result may not denote the same magnitude of thrombotic risk.  
5.2 Laboratory data from 2 potential HIT patients 
We examined 2 patients who experienced thrombocytopenia after being given UFH during 
percutaneous transluminal coronary angioplasty (PTCA) and cardiac surgery. For both 
individuals, we tested for HIT by measuring platelet aggregability and quantifying levels of 
both anti-heparin-PF4 complex antibody (anti-HIT antibody) and thrombin-antithrombin III 
complex (TAT). Platelet aggregation in response to 0.2 μg/mL collagen was measured using 
Born’s turbidimetric methods (Born GVR, 1962), and quantified by light transmission, as 
previously reported (Toyohira et al., 1995; Kariyazono et al., 1997; Nakamura et al., 1999); 
platelet aggregation activity was evaluated as percent maximum aggregation (MA). First 
samples were prepared by incubating the PRP of suspected HIT patients with UFH (0.2 
IU/mL), and second samples were prepared by separately adding plasma from the 2 
patients to the PRP of healthy volunteers at a ratio of 1:1, then adding UFH (0.2 IU/mL). We 
then used a commercial ELISA kit (GTI Diagnostics, Waukesha, WI, NJ, USA) to measure 
anti-heparin antibodies in these samples.  
As shown in Figure 1, platelet aggregation was much higher in the first set of sample than in 
the first control sample (without UFH); in other words, heparin had a strong positive effect 
on aggregation. As a result, MA of second sample was 68% (Figure 2), and showed strong 
aggregation. The ELISA results indicated significantly higher OD values for the 2 potential 
HIT patients than in the healthy volunteers. Furthermore, remarkably high levels of 
circulating TAT and TNF-alpha were found in the plasma of the suspected HIT patients. 
Our laboratory data indicate the likelihood that anti-HIT antibodies were present in the 
plasma of both patients. Furthermore, these data demonstrate the marked acceleration of 
blood coagulation in these patients, suggesting an increased risk of thrombosis.  
These findings support previous reports that many HIT patients are hypercoagulable and 
have greatly elevated levels of TAT (Warkentin et al., 1997; Greinacher et al., 2000); 
furthermore, this helps explain the strong relationship between HIT and venous or arterial 
thrombosis (Warkentin & Kelton, 2001a).  
www.intechopen.com
 
Heparin-Induced Thrombocytopenia 
 
525 
(min)
ヂ
ッ
ツ
 
Fig. 1. Platelet aggregation was stimulated by 0.2 μg/mL collagen. In case A’s PRP 
incubated without UFH (first control sample) (C). In healthy volunteer’s PRP incubated with 
UFH (second control sample) (B). In case A’s PRP incubated with UFH (A).  
(min)
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Fig. 2. Anti-heparin antibody was detected by turbidimetric method. Collagen (0.2 μg/mL) 
was used as agonist. In case A’s PRP incubated without UFH (first control sample) (C). In 
healthy volunteer’s PRP was mixed with case A’s plasma following incubation without UFH 
(third control sample) (B). In healthy volunteer’s PRP was mixed with case A’s plasma 
following incubation with UFH (A).  
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 Given these findings, we propose a model for the pathophysiological mechanism of HIT 
(Figures 3 and 4). This model helps explain observations that the hypercoagulable state, 
coupled with endothelial cell dysfunction due to injury from heparin antibody, activated 
platelets, leukocytes, platelet microparticles, atherosclerosis or medical intervention, can 
lead to arterial thrombosis (Walenga et al., 2000). Furthermore, the model is supported by 
the report that anti-HIT antibodies bind to and directly activate microvascular endothelial 
cells, whereas binding to and activating macrovascular endothelial cells requires pre-
activation by platelets or TNF-alpha (Walenga et al., 2004).  
Release of 
procoagulant 
microparticles
Platelet α-granule
PF4
Heparin
PF4/heparin 
complex
B cell
Anti-PF4/heparin 
complex antibody
Fc receptor
Platelet activation
Release of PF4
 
Fig. 3. Pathophysiological mechanism of HIT (1). Stage 1; binding of heparin to PF4 induces 
the formation of a neoepitope. Stage 2; an immune response against the PF4/heparin 
complex induces antibody formation. Stage 3; the complex of PF4/heparin and specific 
antibody associates with platelets via binding of the antibody Fc part to the platelet 
immunoglobulin receptor FcγRIIa (CD32), representing the major stage in platelet activation 
in HIT. Stage 4; activated platelets shed procoagulant microparticles which enhance 
thrombin generation.  
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Endothelial cells
PF4/glycosaminoglycans
complex
Anti-PF4/glycosaminoglycans
complex antibody
Activated endothelial 
cells
Thrombin
Activated 
factor X
Prothrombin
Microparticles
Thrombus formation
 
Fig. 4. Pathophysiological mechanism of HIT (2). Stage 5; binding of released PF4 to heparan 
sulfate of endothelial cell induces the formation of PF4/glycosaminoglycans complex on the 
surface of endothelial cell. Stage 6; PF4/glycosaminoglycans complex antibody binds to 
PF4/glycosaminoglycans complex on the surface of endothelial cell, and activates 
endothelial cell. Stage 7; activation of endothelial cells lead to the release of activated factor 
X. Stage 8; thrombin generation induces thrombus formation.  
6. Management of HIT 
All heparins must be avoided when treating patients suspected to have HIT; even exposure 
to very low amounts of heparin through heparin-coated catheters and heparin flushes used 
to maintain intravenous lines may trigger HIT (Laster et al., 1989). Likewise, preparations of 
LMWH can induce severe HIT, though they do so less frequently than UFH (Warkentin et 
al., 2003a; Warkentin & Greinacher, 2003; Walenga et al., 2004). Further, the cross-reactivity 
rate between heparin and LMWH is so high that LMWH is not recommended for the 
treatment of HIT patients (Chong, 2003; Warkentin et al., 2008a). Alternative anticoagulant 
therapy must be initiated immediately, both for HIT patients diagnosed with 
thrombocytopenia alone or with thromboembolism (Warkentin & Greinacher, 2004). In 
patients in whom treatment was delayed until an HIT diagnosis could be confirmed by 
laboratory tests, the incidence of new thrombosis was approximately 10-fold higher than in 
individuals treated promptly with a direct thrombin inhibitor (Greinacher et al., 2000).  
Marked decreases of platelet counts in HIT patients require anticoagulation with an effective 
antithrombotic drug that does not cross-react in vivo with the circulating anti-heparin/PF4 
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antibodies. There are currently 3 thrombin inhibitors available for patients with HIT: 
lepirudin, argatroban, and bivalirudin, all of which directly bind and inactivate thrombin. 
Prospective cohort studies have been performed to investigate the efficacy and major 
bleeding endpoints for lepirudin (Greinacher et al., 1999a; Greinacher et al., 1999b; Lubenow 
et al., 2004; Lubenow et al., 2005)  and argatroban (Lewis et al., 2001; Lewis et al., 2003) in 
patients with HIT complicated by thrombosis. When respective historical control data were 
taken into consideration, composite end point risk rates and new thrombosis risk rates were 
0.48 and 0.28 for lepirudin, respectively, and 0.75 and 0.45 for argatroban, respectively. The 
corresponding absolute event rates were 19.2% (lepirudin) and 42.3% (argatroban) for the 
composite end point, and 7.0% (lepirudin) and 15.5% (argatroban) for new thrombosis. 
Patients who received lepirudin were less likely to require amputation than those who were 
given argatroban. Fatal bleeding after treatment with lepirudin has been found to range 
from 1.2% of patients (in a prospective study) to 3.9% of patients (in a retrospective 
observational study) (Lubenow et al., 2005; Tardy et al., 2006). Danaparoid and 
fondaparinux may also be used to manage HIT (Warkentin et al., 2008a). When abrupt 
decreases in platelet count (to <10 × 109 clls/L) are observed in patients who underwent 
angioplasty and were treated with a combination of heparin and glycoprotein IIb/IIIa 
antagonist, the recommended antagonist is always glycoprotein IIb/IIIa (Shantsila et al., 
2009) 
6.1 Lepirudin  
Lepirudin, a recombinant form of hirudin, is a direct, specific, and irreversible inhibitor of 
thrombin that is administered via intravenous injection (Greinacher & Lubenow, 2001). The 
Biggest drawback of Lepirudin is that it must be accompanied by the strict laboratory 
monitoring: activated partial thromboplastin time (aPTT) monitoring should be performed 
at 4-h intervals until it is clear that patients have reached a steady state within the normal 
range of values (Warkentin et al., 2008b). Moreover, patients should be informed that they 
have received lepirudin, since fatal anaphylactic reactions have been reported in patients re-
exposed to lepirudin during a second round of intravenous treatment (Greinacher et al., 
2003). Although similar bleeding rates have been observed in lepirudin-treated patients and 
historical control subjects, this drug has been found to significantly reduce the combined 
end point of death, limb amputation, and new thromboembolic complications in patients 
with HIT associated thrombosis (Greinacher et al., 1999a; Greinacher et al., 1999b). 
6.2 Argatroban  
Argatroban is a synthetic L-arginine-derived direct thrombin inhibitor that reversibly binds 
to the thrombin active site. Argatroban is administered by intravenous injection, with dose 
adjustment to maintain aPTT at 1.5-3.0 times the baseline value (Gosselin et al., 2004). It has 
been reported that, in HIT patients without thrombosis, treatment with argatroban produces 
a significant reduction in the composite end point, such as all-cause death, all-cause limb 
amputation, and new thrombosis at 37 days (Lewis et al., 2001; Lewis et al., 2003). In HIT 
patients who underwent lower extremity revascularization, the composite end point of 
deaths, urgent revascularization, and limb amputations developed in 25% of patients treated 
with argatroban, and 6% of patients had major bleeding episodes (Baron et al., 2008). 
Restoration of platelet counts is universally observed within 6–7 days of the initiation of 
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argatroban therapy (Bartholomew et al., 2007). Some precautions are required when 
argatroban infusion is overlapped by warfarin anticoagulant therapy, although argatroban 
causes a further substantial increase in the international normalized ratio (INR). In addition, 
careful thought should be given to the participation of direct thrombin inhibitor to the 
patient’s INR.  
6.3 Danaparoid  
Danaparoid is approved as an alternative anticoagulant for HIT in many countries. 
Danaparoid, a heparinoid with predominantly anti-Xa activity and some anti-IIa activity, is 
a mixture of three glycosaminoglycans such as heparin sulfate, dermatan sulfate, and 
chondroitin sulfate. Danaparoid presents its anticoagulant effect by catalyzing the 
inactivation of factor Xa in the presence of antithrombin, and has a unique property of 
specific suppression of HIT antibody-induced platelet activation that is not observed with 
other drugs used for HIT treatment (Chong et al., 1989b). Tardy-Poncet et al. reported that 
major bleeding episodes in those patients treated with danaparoid were significantly fewer 
compared with those treated with lepirudin (Tardy-Poncet et al., 1999). Among the drugs 
used for the treatment of HIT, danaparoid is the only drug whose efficacy and safety have 
been confirmed by a prospective randomized controlled study (Chong et al., 2001).  
6.4 Bivalirudin  
Bivalirudin, which is not approved as an HIT treatment, is a 20-amino acid polypeptide with 
sequence homology to hirudin. Campbell et al. (2000) reported 94% procedural success in a 
series of 17 percutaneous coronary intervention patients who were given bivalirudin as a 
treatment for HIT (Campbell et al., 2000). In the Anticoagulant Therapy with Bivalirudin to 
Assist in the Performance of Percutaneous Coronary Intervention in Patients with HIT (or 
ATBAT) multicenter open-label trial (Mahaffey et al., 2003), clinical percutaneous coronary 
intervention success, defined as the absence of death, emergency bypass surgery, or Q-wave 
infarction, was achieved in 96% of patients treated with bivalirudin; further, patients 
displayed a low rate of bleeding. Cumulatively, these results indicate that bivalirudin 
therapy is safe and effective during percutaneous coronary intervention.  
6.5 Fondaparinux 
Fondaparinux, a synthetic pentasaccharide with potent indirect anti-Xa inhibitor properties, 
is used only a limited number of patients with HIT. The generation of HIT-related antigen 
depends on the polysaccharide chain length (Amiral et al., 1995). Because patients have a 
very low risk of developing HIT while receiving fondaparinux (Warkentin et al., 2005), 
platelet count monitoring is not needed during administration of this drug. Despite these 
advantages, fondaparinux cannot be recommended for in the treatment of HIT until there 
are more data demonstrating its efficacy and safety (Rota et al., 2008; Lobo et al., 2008).  
7. Conclusion 
Heparin is one of the most widely used and valuable anticoagulants for the treatment and 
prophylaxis of thrombotic complications. However, HIT is not only a common but also a 
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serious complication of heparin therapy with a high rate of morbidity and mortality. Its 
prompt clinical and laboratory recognition is necessary to stop heparin administration 
immediately and start an alternative anticoagulant. HIT antibody test results must be 
interpreted in the appropriate context of the available clinical information. Furthermore, 
additional diagnostic information is available as a result of considering the magnitude of 
a given positive test result. The diagnosis of HIT should be clearly recorded in the 
patient’s notes and marked as a serious allergy.  
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